An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema

British Journal of Dermatology

Volumn 156, Issue 2, 2007, Pages 346-351

  Weatherhead, S C ^a   Wahie, S ^a   Reynolds, N J ^a   Meggitt, S J ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Atopic eczema; Efficacy; Methotrexate; Quality of life; Safety; Six area six sign atopic dermatitis

Indexed keywords

EMOLLIENT AGENT; METHOTREXATE; STEROID;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HERPES; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM;

ADMINISTRATION, ORAL; ADULT; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33846223886     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07686.x     Document Type: Article

References (18)

1. Herd RM, Tidman MJ, Prescott RJ et al. Prevalence of atopic eczema in the community: the Lothian atopic dermatitis study. Br J Dermatol 1996; 135:18-19.
2. Brown S, Reynolds NJ. Atopic and non-atopic eczema. BMJ 2006; 332:584-8.
3. Egan CA, Rallis TM, Meadows KP et al. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol 1999; 40:612-14.
4. Shaffrali FC, Colver GB, Messenger AG et al. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol 2003; 48:417-19.
5. Goujon C, Berard F, Dahel K et al. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006; 16:155-8.
6. Ellis C, Luger T, Abeck D et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003; 148:3-10.
7. Berth-Jones J. Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996; 135:25-30.
8. Finlay AY, Khan GK. Dermatology life quality index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-16.
9. Williams HC, Burney PG, Pembroke AC et al. The U.K. Working Party's diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131:406-16.
10. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006; 367:839-46.
11. Reynolds NJ, Franklin V, Gray JC et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001; 357:2012-16.
12. Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125:659-64.
13. Berth-Jones J, Takwale A, Tan E et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002; 147:324-30.
14. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005; 57:163-72.
15. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol 2005; 53:652-9.
16. Salim A, Tan E, Ilchyshyn A et al. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, doubleblind, placebo-controlled trial. Br J Dermatol 2006; 154:1169-74.
17. Sowden JM, Berth-Jones J, Ross JS et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338:137-40.
18. Reitamo S, Ortonne JP, Sand C et al., the European Tacrolimus Ointment Study Group. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152:1282-9.